News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Stay if you believe in $CBDL, walk out if you don't. If they don't do another r/s then we are good to go and patience the key!
konshe
Re: PlaySmart2020 post# 85947
Saturday, December 21, 2024 12:47:52 PM
CBDL is a best stock to own. in 2025 NO r/s, no dilution, revenue increasing fast. Good company in good industry.PPS is on bottom, very undervalued, PPS has huge potential to going up. next year PPS can be reached multi pennies for sure.
I think so too, We think positively with best hope—the best is yet to come
CBDL is a best stock to own. in 2025 NO r/s, no dilution, revenue increasing fast. Good company in good industry.PPS is on bottom, very undervalued, PPS has huge potential to going up. next year PPS can be reached multi pennies for sure.
CBDL is preparing for 2025
CBDL is a next year's winner, 0.0004 is a cheap PPS to buy.
0.0004 is a good buy for next year going up to making big money. Company revenue increasing, no No need dilution
HUGE NEWS - 3.5 Billion Share Reduction
Dated Today 12/18/2024
https://www.otcmarkets.com/stock/CBDL/news/CBD-Life-Sciences-Inc-CBDL-Announces-35-Billion-Share-Reduction-From-the-Authorization?id=462712
CBD Life Sciences Inc. (CBDL) Announces 3.5 Billion Share Reduction From the AuthorizationPress Release | 12/18/2024
Demonstrating shareholder confidence, CBDL commits to repurchasing 10% of revenue quarterly.
SCOTTSDALE, AZ / ACCESSWIRE / December 18, 2024 / CBD Life Sciences Inc. (OTC Pink:CBDL), a leading innovator in the CBD and wellness industry, is thrilled to announce a significant milestone in its ongoing commitment to delivering shareholder value. The company has successfully reduced its authorized share count by a staggering 3.5 billion shares. This strategic move underscores CBDL's dedication to strengthening its financial position and enhancing shareholder equity.
This monumental share reduction marks a pivotal moment for CBDL as it continues to streamline its capital structure and build trust with investors. By decreasing the number of authorized shares, CBDL aims to reduce dilution, increase stock value, and solidify its reputation as a company that prioritizes its shareholders' interests. This is a clear signal to the market that CBDL is committed to fostering sustainable growth while putting its shareholders first.
Key Benefits of the Share Reduction Initiative:
Enhanced Stock Value: By significantly reducing authorized shares, CBDL positions itself to offer greater value to shareholders, reflecting positively on stock performance and market sentiment.
Increased Investor Confidence: Demonstrates CBDL's long-term commitment to aligning with shareholder goals and building a robust and transparent financial framework.
Strategic Financial Management: Signals a disciplined approach to capital management, paving the way for stronger financial performance and long-term profitability.
In addition to this bold initiative, CBDL has announced a groundbreaking new policy to repurchase 10% of its revenue in stock each quarter. This progressive strategy not only underscores CBDL's confidence in its business model but also reinforces its dedication to returning value directly to shareholders. "By reinvesting in our own stock, we're showing that we're not just talking about growth-we're actively creating it," said Lisa Nelson, President and CEO of CBDL. "This move reflects our optimism about the future and our unwavering commitment to maximizing shareholder value."
The share reduction comes on the heels of an impressive 1405.46% revenue growth since February 2024, driven by the company's expanding product line and strategic retail partnerships, including Walmart Marketplace. This explosive growth highlights the success of CBDL's innovative product offerings, such as the highly sought-after 3000MG Pain Relief Cream and Delta 8 Gummies. These products are not only meeting the needs of a rapidly growing market but also setting the standard for quality and effectiveness in the CBD industry.
CBDL's leadership continues to pave the way for an exciting future. The company's visionary approach and relentless focus on innovation, sustainability, and customer satisfaction have positioned it as a trailblazer in the wellness sector. The decision to reduce shares and repurchase stock underscores the confidence CBDL's management has in its strategic direction and its ability to deliver tangible results for investors.
As CBDL looks ahead, the company remains steadfast in its mission to revolutionize the CBD industry with cutting-edge products and a commitment to excellence. With a robust pipeline of initiatives, including new product launches and expanded retail partnerships, the future is brighter than ever for CBD Life Sciences Inc.
About CBD Life Sciences Inc. CBD Life Sciences Inc. (OTC: CBDL) is at the forefront of the CBD and wellness revolution. The company offers a diverse range of high-quality CBD-based products, leveraging advanced nanotechnology and sustainable practices to deliver superior solutions for consumers and businesses alike. With a focus on innovation and investor confidence, CBDL is redefining the future of wellness.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information:
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
SOURCE: CBD Life Sciences Inc.
View the original press release on accesswire.com
https://www.otcmarkets.com/stock/CBDL/news/CBD-Life-Sciences-Inc-CBDL-Announces-35-Billion-Share-Reduction-From-the-Authorization?id=462712
$CBDL CBD Life Sciences Inc. (CBDL) Announces 3.5 Billion Share Reduction From the Authorization
https://www.accesswire.com/956484/cbd-life-sciences-inc-cbdl-announces-35-billion-share-reduction-from-the-authorization
Demonstrating shareholder confidence, CBDL commits to repurchasing 10% of revenue quarterly.
SCOTTSDALE, AZ / ACCESSWIRE / December 18, 2024 / CBD Life Sciences Inc. (OTC Pink:CBDL), a leading innovator in the CBD and wellness industry, is thrilled to announce a significant milestone in its ongoing commitment to delivering shareholder value. The company has successfully reduced its authorized share count by a staggering 3.5 billion shares. This strategic move underscores CBDL's dedication to strengthening its financial position and enhancing shareholder equity.
This monumental share reduction marks a pivotal moment for CBDL as it continues to streamline its capital structure and build trust with investors. By decreasing the number of authorized shares, CBDL aims to reduce dilution, increase stock value, and solidify its reputation as a company that prioritizes its shareholders' interests. This is a clear signal to the market that CBDL is committed to fostering sustainable growth while putting its shareholders first.
Key Benefits of the Share Reduction Initiative:
Enhanced Stock Value: By significantly reducing authorized shares, CBDL positions itself to offer greater value to shareholders, reflecting positively on stock performance and market sentiment.
Increased Investor Confidence: Demonstrates CBDL's long-term commitment to aligning with shareholder goals and building a robust and transparent financial framework.
Strategic Financial Management: Signals a disciplined approach to capital management, paving the way for stronger financial performance and long-term profitability.
In addition to this bold initiative, CBDL has announced a groundbreaking new policy to repurchase 10% of its revenue in stock each quarter. This progressive strategy not only underscores CBDL's confidence in its business model but also reinforces its dedication to returning value directly to shareholders. "By reinvesting in our own stock, we're showing that we're not just talking about growth-we're actively creating it," said Lisa Nelson, President and CEO of CBDL. "This move reflects our optimism about the future and our unwavering commitment to maximizing shareholder value."
The share reduction comes on the heels of an impressive 1405.46% revenue growth since February 2024, driven by the company's expanding product line and strategic retail partnerships, including Walmart Marketplace. This explosive growth highlights the success of CBDL's innovative product offerings, such as the highly sought-after 3000MG Pain Relief Cream and Delta 8 Gummies. These products are not only meeting the needs of a rapidly growing market but also setting the standard for quality and effectiveness in the CBD industry.
CBDL's leadership continues to pave the way for an exciting future. The company's visionary approach and relentless focus on innovation, sustainability, and customer satisfaction have positioned it as a trailblazer in the wellness sector. The decision to reduce shares and repurchase stock underscores the confidence CBDL's management has in its strategic direction and its ability to deliver tangible results for investors.
As CBDL looks ahead, the company remains steadfast in its mission to revolutionize the CBD industry with cutting-edge products and a commitment to excellence. With a robust pipeline of initiatives, including new product launches and expanded retail partnerships, the future is brighter than ever for CBD Life Sciences Inc.
When the OTC flash flood hits, all boats will rise, every dog has it's day in the OTC!
CBD Life Sciences Inc. (CBDL) Looking to Acquire a Cannabis Growth License in North Las VegasPress Release | 12/11/2024
Target Acquisition Valued at $10 Million with Projected 2025 Gross Revenue of $5 Million, Positioning CBDL for Explosive Growth in Nevada's Burgeoning Cannabis Market
SCOTTSDALE, AZ / ACCESSWIRE / December 11, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), a leader in CBD innovation, announces its intent to acquire a cannabis growth license in North Las Vegas, a move that could serve as a transformative step in the company's evolution. With a target business value of $10 million and a projected $5 million in gross revenue by 2025, this acquisition positions CBDL at the forefront of Nevada's thriving cannabis cultivation market, which is projected to surpass $1.3 billion by 2025.
Expanding beyond its already successful CBD product portfolio, this acquisition will enable CBDL to enter the cannabis cultivation and distribution space, capitalizing on the robust demand for high-quality cannabis products in Nevada and across the nation. This strategic pivot is set to unlock significant revenue potential while solidifying the company's status as a dual-market powerhouse in both CBD and cannabis.
The Nevada Cannabis Market: A Strategic Opportunity
Nevada is one of the most dynamic cannabis markets in the United States, driven by strong consumer demand, progressive regulations, and a booming tourism industry. North Las Vegas, located within Clark County, offers a unique advantage for cannabis cultivation due to its proximity to Las Vegas' 40+ million annual tourists and access to key distribution channels. With legalization trends continuing to sweep the nation, Nevada's cannabis market remains a critical growth hub for companies like CBDL.
Securing a cannabis growth license in this region offers unparalleled potential. Cannabis cultivation facilities in Nevada have demonstrated the ability to generate annual revenues ranging from $1.5 million to $5 million, depending on scale and efficiency. For CBDL, this venture could create new revenue streams and provide significant competitive advantages in an increasingly crowded marketplace.
Diversifying Revenue and Strengthening Market Position
The cannabis growth license acquisition aligns with CBDL's long-term strategy of diversification and growth. In addition to providing a new revenue channel, this venture allows the company to vertically integrate its operations, controlling production quality while reducing costs. Vertical integration is particularly advantageous in the cannabis industry, where consistency, compliance, and quality are key differentiators.
By producing cannabis in-house, CBDL gains greater control over the supply chain and opens doors to additional high-margin opportunities, including:
White-label partnerships with other cannabis brands.
Direct-to-consumer sales through dispensaries.
Product development leveraging CBDL's expertise in formulating premium CBD products.
This expansion also strengthens CBDL's ability to cater to diverse consumer preferences, from recreational cannabis users to medical patients seeking relief through high-quality cannabis products.
Revenue Projections That Excite
As part of this expansion, CBDL anticipates a substantial increase in its revenue trajectory. The company's current growth momentum, evidenced by a 1,405.46% revenue increase since February 2024, underscores its ability to scale effectively and capitalize on new opportunities. The projected $5 million in gross revenue from this cannabis growth license by 2025 could propel CBDL to new heights, allowing it to reinvest in operations, marketing, and product innovation.
Additionally, the Nevada cannabis market benefits from one of the most business-friendly taxation systems in the country, providing further incentives for long-term profitability. Coupled with its flourishing tourism industry and expanding local customer base, this acquisition represents a near-perfect synergy between market opportunity and company capabilities.
Endless Possibilities for Growth and Innovation
The cannabis industry is evolving at an unprecedented pace, with significant advancements in cultivation technology, product innovation, and consumer awareness. By establishing a foothold in North Las Vegas, CBDL can leverage these trends to develop cutting-edge products that appeal to a wide range of consumers. The potential for partnerships with dispensaries, research institutions, and wellness companies further underscores the limitless growth opportunities this acquisition presents.
"This is not just another step for CBD Life Sciences Inc. - it's a leap toward redefining our company's future," said Lisa Nelson, President and CEO of CBDL. "With a cannabis growth license in North Las Vegas, we are positioned to accelerate our growth, diversify our portfolio, and deliver unmatched value to our shareholders."
Looking Ahead: A Bright Future for CBDL
CBDL's entrance into the cannabis cultivation market represents a monumental shift in its operational strategy, but it's only the beginning. As the company continues to explore expansion opportunities in Nevada and other high-growth regions, shareholders and investors can expect exciting updates in the months ahead.
The acquisition of this growth license is more than a business move - it's a testament to CBDL's commitment to innovation, growth, and shareholder value. With the cannabis and CBD markets projected to reach record-breaking revenues in the coming years, CBDL is positioning itself as a trailblazer in the wellness industry.
For more information, please visit CBD Life Sciences Inc.
About CBD Life Sciences Inc.
CBD Life Sciences Inc. (OTC:CBDL) is a leader in the CBD and wellness industries, specializing in premium CBD products and innovative solutions. With a proven track record of growth and a forward-thinking approach, CBDL continues to expand its presence in emerging markets, driving shareholder value and industry leadership.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information:
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
Related Images
SOURCE: CBD Life Sciences Inc.
https://www.otcmarkets.com/stock/CBDL/news/CBD-Life-Sciences-Inc-CBDL-Looking-to-Acquire-a-Cannabis-Growth-License-in-North-Las-Vegas?id=461963
$CBDL CBD Life Sciences Inc. (CBDL) Looking to Acquire a Cannabis Growth License in North Las Vegas
https://www.accesswire.com/952724/cbd-life-sciences-inc-cbdl-looking-to-acquire-a-cannabis-growth-license-in-north-las-vegas
Target Acquisition Valued at $10 Million with Projected 2025 Gross Revenue of $5 Million, Positioning CBDL for Explosive Growth in Nevada's Burgeoning Cannabis Market
SCOTTSDALE, AZ / ACCESSWIRE / December 11, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), a leader in CBD innovation, announces its intent to acquire a cannabis growth license in North Las Vegas, a move that could serve as a transformative step in the company's evolution. With a target business value of $10 million and a projected $5 million in gross revenue by 2025, this acquisition positions CBDL at the forefront of Nevada's thriving cannabis cultivation market, which is projected to surpass $1.3 billion by 2025.
Expanding beyond its already successful CBD product portfolio, this acquisition will enable CBDL to enter the cannabis cultivation and distribution space, capitalizing on the robust demand for high-quality cannabis products in Nevada and across the nation. This strategic pivot is set to unlock significant revenue potential while solidifying the company's status as a dual-market powerhouse in both CBD and cannabis.
The Nevada Cannabis Market: A Strategic Opportunity
Nevada is one of the most dynamic cannabis markets in the United States, driven by strong consumer demand, progressive regulations, and a booming tourism industry. North Las Vegas, located within Clark County, offers a unique advantage for cannabis cultivation due to its proximity to Las Vegas' 40+ million annual tourists and access to key distribution channels. With legalization trends continuing to sweep the nation, Nevada's cannabis market remains a critical growth hub for companies like CBDL.
Securing a cannabis growth license in this region offers unparalleled potential. Cannabis cultivation facilities in Nevada have demonstrated the ability to generate annual revenues ranging from $1.5 million to $5 million, depending on scale and efficiency. For CBDL, this venture could create new revenue streams and provide significant competitive advantages in an increasingly crowded marketplace.
Diversifying Revenue and Strengthening Market Position
The cannabis growth license acquisition aligns with CBDL's long-term strategy of diversification and growth. In addition to providing a new revenue channel, this venture allows the company to vertically integrate its operations, controlling production quality while reducing costs. Vertical integration is particularly advantageous in the cannabis industry, where consistency, compliance, and quality are key differentiators.
By producing cannabis in-house, CBDL gains greater control over the supply chain and opens doors to additional high-margin opportunities, including:
White-label partnerships with other cannabis brands.
Direct-to-consumer sales through dispensaries.
Product development leveraging CBDL's expertise in formulating premium CBD products.
This expansion also strengthens CBDL's ability to cater to diverse consumer preferences, from recreational cannabis users to medical patients seeking relief through high-quality cannabis products.
Revenue Projections That Excite
As part of this expansion, CBDL anticipates a substantial increase in its revenue trajectory. The company's current growth momentum, evidenced by a 1,405.46% revenue increase since February 2024, underscores its ability to scale effectively and capitalize on new opportunities. The projected $5 million in gross revenue from this cannabis growth license by 2025 could propel CBDL to new heights, allowing it to reinvest in operations, marketing, and product innovation.
Additionally, the Nevada cannabis market benefits from one of the most business-friendly taxation systems in the country, providing further incentives for long-term profitability. Coupled with its flourishing tourism industry and expanding local customer base, this acquisition represents a near-perfect synergy between market opportunity and company capabilities.
Endless Possibilities for Growth and Innovation
The cannabis industry is evolving at an unprecedented pace, with significant advancements in cultivation technology, product innovation, and consumer awareness. By establishing a foothold in North Las Vegas, CBDL can leverage these trends to develop cutting-edge products that appeal to a wide range of consumers. The potential for partnerships with dispensaries, research institutions, and wellness companies further underscores the limitless growth opportunities this acquisition presents.
"This is not just another step for CBD Life Sciences Inc. - it's a leap toward redefining our company's future," said Lisa Nelson, President and CEO of CBDL. "With a cannabis growth license in North Las Vegas, we are positioned to accelerate our growth, diversify our portfolio, and deliver unmatched value to our shareholders."
Looking Ahead: A Bright Future for CBDL
CBDL's entrance into the cannabis cultivation market represents a monumental shift in its operational strategy, but it's only the beginning. As the company continues to explore expansion opportunities in Nevada and other high-growth regions, shareholders and investors can expect exciting updates in the months ahead.
The acquisition of this growth license is more than a business move - it's a testament to CBDL's commitment to innovation, growth, and shareholder value. With the cannabis and CBD markets projected to reach record-breaking revenues in the coming years, CBDL is positioning itself as a trailblazer in the wellness industry.
For more information, please visit CBD Life Sciences Inc.
BIG OPPORTUNITY COMING NEXT WEEK, STAY TUNED $CBDL
$CBDL huge move is imminent folks. Load and hold. https://x.com/CBDL_StockOTC/status/1865037351228944586
|
Followers
|
723
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
85958
|
|
Created
|
09/21/07
|
Type
|
Free
|
| Moderators resx18 SmellMyFinger | |||
AI
